# FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Source: https://onco.cc/trials/nct06669117/  
OnCo record `nct06669117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VERT-002 in advanced solid tumours, run by Pierre Fabre Medicament, now recruiting.

## Summary

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations is a phase 1/2 interventional study registered as NCT06669117 by Pierre Fabre Medicament, with 140 participants planned, started 2024-10-22 and due to reach its primary completion in 2030-10-21. Interventions recorded: VERT-002.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06669117
- Phase: 1/2
- Setting: A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations
- Sponsor: Pierre Fabre Medicament
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT06669117: https://clinicaltrials.gov/study/NCT06669117

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06669117.json